Page 173 - IJB-10-6

International Journal of Bioprinting 3D bioprinting technology for brain tumor

subjected to PDTs with TMZ. The median viability of of RSL and dasatinib, this cluster is a promising candidate
these compounds was 5.8%, 4.2%, and 50%, respectively. for the treatment of GBM. In addition, PDTs treated with
153
RSL, dasatinib, lovastatin, and TMZ were identified in CCNU, cisplatin, lobaplatin, dasatinib, lovastatin, and
three distinct clusters according to the overall GlioML RSL demonstrated remarkably reduced tumor viability
predictions for all patient samples. Based on the efficacy compared with that of non-treated cells. As PDTs align

Figure 6. Application and characterization of patient-derived tissues (PDTs). (A) Schematic overview of PDT generation. The PDT model facilitates drug
screening and mechanistic studies via RNA sequencing, whole exome sequencing, and flow cytometry. (B) Representative immunofluorescent staining of
PDTs displays CD45 (green), a marker for immune cells, and GFAP (red), a marker for glial cells, in two different patient samples (1779-HS and 29259-
HS). (C) Venn diagrams indicate the genomic concordance between two patient tissue samples and their PDTs. The concordance ratio for each comparison
exceeded over 90%, indicating high similarity. Adapted from ref. 153

Volume 10 Issue 6 (2024) 165 doi: 10.36922/ijb.4166